Phytoecdysone Mas Receptor Activation for Viral ARDS

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for respiratory insufficiency and acute respiratory distress syndrome (ARDS) caused by viral infections, particularly those induced by coronaviruses like SARS-CoV and SARS-CoV-2, disrupt the angiotensin-renin system (ARS) imbalance, leading to pulmonary vasoconstriction and inflammatory lesions, and existing interventions like ACE inhibitors and AT1 receptor antagonists are risky and ineffective.

Innovation Solution

The use of phytoecdysones and semisynthetic derivatives to directly activate the 'protecting' arm of the ARS via the Mas receptor, restoring balance by enhancing the ACE2/Ang-1-7/MasR axis without affecting cardiovascular parameters or respiratory functions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If ACE inhibitors or AT1 receptor antagonists are used to treat respiratory insufficiency caused by viral infections, then the ARS imbalance is disrupted, but pulmonary vasoconstriction and inflammatory lesions worsen

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidpulmonary vasoconstriction and inflammatory lesions

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Instead of inhibiting the harmful ACE/AngII/AT1 axis as in conventional therapy, this patent activates the protective ACE2/Ang1-7/MasR axis through phytoecdysones. This inverted approach shifts therapeutic focus from blocking harmful pathways to enhancing protective pathways, thereby treating respiratory insufficiency without causing pulmonary vasoconstriction and inflammatory lesions

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

Phytoecdysones act as intermediary substances that selectively activate the MasR receptor, thereby stimulating the protective ARS axis without directly interfering with the harmful ACE/AngII/AT1 pathway. This mediator approach allows balanced modulation of the ARS system, improving treatment effectiveness while avoiding harmful side effects

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If the ACE2/Ang-1-7/MasR axis is activated to restore ARS balance, then respiratory function improves, but cardiovascular parameters and respiratory flow rates are affected

Engineering Contradiction:

Improverespiratory functionVSAvoidhypotensive effects and respiratory flow rate changes

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The phytoecdysone treatment selectively activates the protective ARS axis specifically in pulmonary tissue, achieving localized therapeutic effect on respiratory function. This local action spares cardiovascular parameters and respiratory flow rates from significant changes, as the protective axis activation is concentrated where needed rather than systemically affecting all organ systems

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS12551495B2Phytoecdysones and derivatives thereof for use in treating disordered respiratory function on viral infection

Publication Date: 2026.02.17 BIOPHYTIS

AI summary

Disclosed are phytoecdysones and semisynthetic derivatives of phytoecdysones, intended to be used in treating impairment of the respiratory function in mammals, in particular in the context of a viral infection and more particularly during an infection by a coronavirus.